Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (10,642)	$ (9,452)
Loss from discontinued operations	(3,049)	(4,136)
Loss from continuing operations	(7,593)	(5,316)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,029	1
Stock-based compensation expense	855	560
Loss on disposition of property & equipment	0	1
Board fees paid with common stock	195	0
Change in fair value of common stock warrants	29	(1,323)
Non-cash expense of issuing shares to Aspire Capital	602	0
Change in operating assets and liabilities:
Accounts receivable	3	0
Prepaid expenses and other assets	101	(52)
Other long-term assets	0	(49)
Accounts payable	232	336
Accrued compensation and other current liabilities	(74)	(166)
Other long-term liabilities	(20)	52
Net cash used in continuing operating activities	(4,641)	(5,956)
Net cash used in discontinued operating activities	(2,577)	(4,853)
Net cash used in operating activities	(7,218)	(10,809)
Cash flows from investing activities:
Costs of Essentialis acquisition paid	(573)	0
Purchase of property and equipment	(4)	(22)
Net cash used in continuing investing activities	(577)	(22)
Net cash provided by (used for) discontinued investing activities	716	(17)
Net cash used in investing activities	139	(39)
Cash flows from financing activities:
Redemption of Series A preferred stock in conjunction with issuance of Series B preferred stock	0	(7,780)
Proceeds from issuance of common stock	10,000	70
Net cash provided by continuing financing activities	10,000	10,768
Net cash provided by discontinued financing activities	0	0
Net cash provided by financing activities	10,000	10,768
Net increase (decrease) in cash and cash equivalents	2,921	(80)
Cash and cash equivalents, beginning of period	2,726	5,495
Cash and cash equivalents, end of period	5,647	5,415
Supplemental disclosures of non-cash investing and financing information
Conversion of Series A preferred to common stock	0	2,220
Issuance of common stock in Essentialis acquisition	18,764	0
Contingent consideration of Essentialis acquisition	1,090	0
Series B preferred transactions costs in accounts payable	0	52
Fixed asset purchases in accounts payable	0	11
Series A Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from sale of Series A preferred convertible stock	0	5,070
Series A preferred convertible stock transaction costs paid	0	(71)
Series B Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from sale of Series A preferred convertible stock	0	13,479
Series B Convertible Preferred Stock [Member] | Cash Less Exercise [Member]
Supplemental disclosures of non-cash investing and financing information
De-recognition of Series B warrant liability (cashless exercise)	0	593
Continuing Operations [Member]
Cash flows from financing activities:
Net increase (decrease) in cash and cash equivalents	4,783	4,790
Discontinued Operations [Member]
Cash flows from financing activities:
Net increase (decrease) in cash and cash equivalents	$ (1,862)	$ (4,870)